By Dr Alvin Kamili

Preprints

Jung M; Poltavets V; Skhinas JN; Tax G; Kamili A; Xie A; Ghamrawi S; Graber P; Mao J; Wong-Erasmus M; Cui L; Kimpton K; Venkat P; Mayoh C; Fleuren EDG; Fordham AM; Barger Z; Grady J; Thomas DM; Du EY; Cowley MJ; Gifford AJ; Fletcher JI; Lau LMS; Dolman MEM; Gooding JJ; Kavallaris M, Engineered paediatric tumours retain maintains tumour genotype and phenotype for precision medicine, http://dx.doi.org/10.1101/2024.11.17.619539

Han JZR; Phimmachanh M; Hastings JF; Leong H; Ng BH; Ni J; Fontaine-Titley A; Cadell AL; O’Donnell YE; Clearwater M; Kamili A; Haber M; Norris M; Timpson P; Trahair TN; Fletcher JI; Fey D; Kolch W; Latham SL; Croucher DR, Inclusion of JNK-independent drugs within multi-agent chemotherapy improves response in relapsed high-risk neuroblastoma, http://dx.doi.org/10.1101/2025.04.26.650760

Kamili A; Hearn BA; Temelkoska I; Solomon J; Wheatley MS; Bui CHT; Atkinson CJ; Elhassadi L-J; Qureshi S; Murray J; Cadiz R; Gifford AJ; Cui L; Crowley L; Lin A; Mayoh C; Wong-Erasmus M; Failes TW; Arndt GM; Haber M; Norris MD; Dolman MEM; Trahair TN; Fletcher JI, Preclinical trial supports dual inhibition of BCL2 and Aurora kinase A for MYCN -amplified high-risk neuroblastoma, http://dx.doi.org/10.64898/2026.09.06.749004

Back to profile page